Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by longterm56on Jun 02, 2021 8:22pm
132 Views
Post# 33316291

RE:RE:RE:RE:No trades

RE:RE:RE:RE:No tradesI'm going to step out on a limb and say that this weekly report card thingy is ... at best ... extremely arrogant to think you can judge their weekly activities without knowing any of the details that they do ... and at worst ... it could tick them off enough (if they even read this board)  to continue in the ways that you feel are deficient.  I can hear them say ... "Yea, let's not announce that yet and really stick it to the long term shareholders on Stockhouse." 

As shareholders, we have one opportunity per year to effectively "give them a grade" ... and this year we gave them a "Satisfactory" by not voting anyone off the board. And then a few weeks later we judge them weekly with scores of D & F???   Seriously??? What has changed since the week of the AGM? 

SPCEO, how would you like it if your clients graded you weekly based on the performance of your investments (including THTX) ... something like ... "In the biggest bull run in history SPCEO has us in THTX???  That's a clear F!!!! "    I think you would say to yourself ...  I know more details than they do and  they don't understand it the way I do ... and continue on in your ways. Just like THTX. 

   -LT  



SPCEO1 wrote: There is still time for TH to avoid that fate. But there is no denying the week is off to a slow start. Hopefully, what we are seeing is the calm before they unleash an IR storm and that their time is being consumed by putting the finishing touches on the Great Rebranding. Maybe we can move on from the OO to the GR.
stockman75 wrote: I am going to go out on a strong limb and guess we get another D to F report this week! 




<< Previous
Bullboard Posts
Next >>